Irv Weissman's lab spins out another biotech, with help of Forty Seven co-founders, to target new 'don't eat me' signal

Kyle LaHucik

Senior Reporter

At age 24, while in Irv Weissman’s lab, Amira Barkal realized the CD24 protein was another “don’t eat me” signal for cancers. Weissman, the Stanford …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Irv Weissman's lab spins out another biotech, with help of Forty Seven co-founders, to target new 'don't eat me' signal

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Patient dies in Neurogene's Rett syndrome study

Are programs with compounded GLP-1s safe for your population?

Irv Weiss­man­'s lab spins out an­oth­er biotech, with help of Forty Sev­en co-founders, to tar­get new 'don't eat me' sig­nal

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Irv Weissman's lab spins out another biotech, with help of Forty Seven co-founders, to target new 'don't eat me' signal

Trump names Johns Hopkins researcher Marty Makary to lead the FDA

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Patient dies in Neurogene's Rett syndrome study

Are programs with compounded GLP-1s safe for your population?